Clinical trials: Monoclonal Antibody
Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS)
Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 in Blood Samples
the main objectives are 1. to study the pathophysiological role of KIR3DL2 in axSpA and its relationship with Th17 immunity in HLA-B27 + and HLA-B27- patients and 2.
- Trial name
- KIR3DL2 (NCT03322618)
- Testing
- blood samples
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Advanced Hepatocellular Carcinoma
HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
This study is conducted in patients with advanced hepatocellular carcinoma (HCC). This study includes three arms: A, B, and C. Arm A will receive HLX07 combination therapy with HLX10 and HLX04 as first line treatment.
- Trial name
- NCT05290220
- Testing
- HLX07, HLX10, HLX04
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Epithelial Cancer Patients
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
The study is designed as an open-label dose-escalation study to investigate the safety and tolerability of catumaxomab qwk in patients with epithelial cancer.
- Trial name
- NCT01320020
- Testing
- catumaxomab
- Where
- 3 sites in Austria, Denmark and 1 more
- Volunteers
- 16 people
- Sponsor
- Neovii Biotech
Diffuse Cutaneous Systemic Sclerosis
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Trial name
- NCT07287670
- Testing
- MTX-474
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 85 people
- Sponsor
- Mediar Therapeutics
HIV Infections
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of an antibody (called VRC01) in HIV-infected adults whose HIV was well-controlled with HIV medicines.
- Trial name
- NCT02463227
- Testing
- VRC01
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Epithelial Ovarian Cancer
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
The purpose of this study is to establish the safest dose of MORAb-003 in subjects with advanced ovarian cancer. MORAb-003 is an antibody directed to an antigen on the surface of ovarian cancer cells.
- Trial name
- NCT00428766
- Testing
- MORAb-003
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Morphotek
Breast Cancer
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming…
- Trial name
- NCT00028483
- Testing
- cBR96-doxorubicin immunoconjugate, docetaxel
- Where
- United States
- Sponsor
- Seagen Inc.
Crohn Disease
Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.
This study is a proof of concept, multi-center, randomized, double-blind, placebo-controlled, parallel-group phase 2 dose-ranging study of BI 655066/ABBV-066 (risankizumab), an IL-23 p19 antagonist monoclonal antibody, in…
- Trial name
- NCT02031276
- Testing
- risankizumab IV, risankizumab SC
- Volunteers
- 121 people
- Sponsor
- AbbVie
Multiple Sclerosis, Relapsing-Remitting
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis.
- Trial name
- ANGEL-MS (NCT03239860)
- Testing
- GNbAC1 Monoclonal Antibody
- Where
- 12 sites in Bulgaria, Croatia and 10 more
- Volunteers
- 220 people
- Sponsor
- GeNeuro SA
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)
- Trial name
- EMBODY1 (NCT01262365)
- Testing
- Epratuzumab
- Where
- 141 sites in United States, Australia and 19 more
- Volunteers
- 793 people
- Sponsor
- UCB Pharma
Systemic Lupus Erythematosus
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of thie study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of belimumab (LymphoStat-B™)in subjects with SLE.
- Trial name
- NCT00657007
- Testing
- belimumab
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- Human Genome Sciences Inc.
Psoriasis
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to…
- Trial name
- NAVIGATE (NCT02203032)
- Testing
- Ustekinumab, Guselkumab
- Where
- 85 sites in United States, Australia and 8 more
- Volunteers
- 872 people
- Sponsor
- Janssen Research & Development, LLC
Dermatitis, Atopic, Eczema, Atopic
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination…
- Trial name
- NCT06554847
- Testing
- 611, Topical corticosteroid
- Where
- 3 sites in China
- Volunteers
- 417 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
HIV-1 Infection
3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption
This study evaluates the effects of two infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART and its safety during a brief analytical interruption of…
- Trial name
- NCT02446847
- Testing
- 3BNC117, ART Interruption
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Rockefeller University
Patients With Intransit Stage III/IV Melanoma
Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma
In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.
- Trial name
- NCT01213732
- Testing
- Isolated inferior limb perfusion
- Where
- 2 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Philogen S.p.A.
Lymphoma
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma.
- Trial name
- NCT04464798
- Testing
- CC-220, Rituximab, Obinutuzumab
- Where
- 26 sites in United States, France and 4 more
- Volunteers
- 62 people
- Sponsor
- Celgene
Locally Advanced Rectal Cancer
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.
- Trial name
- NCT07469306
- Testing
- Modified Short-course radiotherapy, Long-course radiotherapy, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fujian Cancer Hospital
Delayed Graft Function
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
When a patient receives a kidney transplant particularly if the kidney is from an older donor or one who has had the kidney removed after their heart has stopped, there is a risk that the newly transplanted kidney may not…
- Trial name
- NCT01794663
- Testing
- OPN-305
- Where
- 50 sites in United States, Austria and 9 more
- Volunteers
- 252 people
- Sponsor
- Opsona Therapeutics Ltd.
Crohn Disease
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 [NCT00552058].
- Trial name
- NCT00552344
- Testing
- Cimzia
- Where
- 100 sites in United States, Australia and 16 more
- Volunteers
- 403 people
- Sponsor
- UCB BIOSCIENCES GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.